Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission
Open Access
- 5 November 2007
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 41 (1) , 33-38
- https://doi.org/10.1038/sj.bmt.1705879
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AMLBest Practice & Research Clinical Haematology, 2006
- Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromesBlood, 2006
- Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correctLeukemia, 2006
- Allogeneic Transplantation for the Elderly Patient With Acute Myelogenous Leukemia or Myelodysplastic SyndromeSeminars in Hematology, 2006
- Hematopoietic cell transplantation in first complete remission versus early relapseBest Practice & Research Clinical Haematology, 2006
- Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensityLeukemia, 2005
- Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysisLeukemia, 2005
- Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningBlood, 2004
- Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationBlood, 2004
- STEM CELL TRANSPLANTATIONFOR LEUKEMIAS FOLLOWING MYELODYSPLASTIC SYNDROMESOR SECONDARYTO CYTOTOXIC THERAPYReviews in Clinical and Experimental Hematology, 2002